Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2017

The transcription factor Foxo1 controls germinal center B cell
proliferation in response to T cell help
Takeshi Inoue
Osaka University

Ryo Shinnakasu
Osaka University

Wataru Ise
Osaka University

Chie Kawai
Osaka University

Takeshi Egawa
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Inoue, Takeshi; Shinnakasu, Ryo; Ise, Wataru; Kawai, Chie; Egawa, Takeshi; and Kurosaki, Tomohiro, ,"The
transcription factor Foxo1 controls germinal center B cell proliferation in response to T cell help." The
Journal of Experimental Medicine. 214,4. 1181-1198. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5715

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Takeshi Inoue, Ryo Shinnakasu, Wataru Ise, Chie Kawai, Takeshi Egawa, and Tomohiro Kurosaki

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/5715

Ar ticle

The transcription factor Foxo1 controls germinal center
B cell proliferation in response to T cell help
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and Tomohiro Kurosaki1,2
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G erminal center (GC) B cells cycle between two states, the light zone (LZ) and the dark zone (DZ), and in the latter they proliferate and hypermutate their immunoglobulin genes. How this functional transition takes place is still controversial. In this
study, we demonstrate that ablation of Foxo1 after GC development led to the loss of the DZ GC B cells and disruption of the
GC architecture, which is consistent with recent studies. Mechanistically, even upon provision of adequate T cell help,
Foxo1-deficient GC B cells showed less proliferative expansion than controls. Moreover, we found that the transcription factor
BATF was transiently induced in LZ GC B cells in a Foxo1-dependent manner and that deletion of BATF similarly led to GC
disruption. Thus, our results are consistent with a model where the switch from the LZ to the DZ is triggered after receipt of
T cell help, and suggest that Foxo1-mediated BATF up-regulation is at least partly involved in this switch.
Introduction
After their initial encounter with T cell–dependent antigens,
B cells migrate to the interface between the T and B cell
zones in lymphoid organs, where they interact with cognate
T cells to form antigen-specific cell clusters.After leaving these
clusters, B cells undergo brisk proliferation before entering
the GC reaction or developing into short-lived plasmablasts
(herein called the preGC period;Victora and Mesin, 2014; De
Silva and Klein, 2015).
Once a GC is established in the B cell follicle, the dark
zone (DZ) and light zone (LZ) form and the GC B cells
then cycle between them (Allen et al., 2007;Victora and Nussenzweig, 2012). B cells in these two zones can be identified
based on expression levels of the signature surface proteins
CXCR4, CD83, and CD86; DZ GC cells express higher levels of CXCR4, but lower levels of CD83 and CD86, whereas
LZ cells are CXCR4low, CD83hi, and CD86hi. Proliferation
and somatic hypermutation (SHM) occur in the DZ, and
then the B cells shuttle to the LZ, where they exit the cell
cycle. In the LZ, de novo mutated BCRs capture antigen and
internalize it for MHC class II (MHC-II) presentation to follicular helper T (TFH) cells. According to the current model
(Allen et al., 2007; Victora et al., 2010; Liu et al., 2015), GC
B cells expressing high-affinity BCRs are selected in response
to signals provided by cognate TFH cells in the LZ. Next, as
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cells transit from the LZ back to the DZ, proliferation is induced. Therefore, it has been argued that induction of proliferation after receipt of TFH cell help is well coupled to the
LZ-to-DZ transition. Ultimately, after several such iterative
cycles of proliferation, diversification, and selection, the GC
generates high-affinity plasma cells and memory B cells.
In regard to the molecular processes for DZ cyclic reentry, it has been demonstrated that c-Myc plays an important
role because it is expressed by a small fraction of LZ GC
B cells that are enriched for high-affinity BCRs and have
recently entered the S phase of the cell cycle (Calado et
al., 2012; Dominguez-Sola et al., 2012; Gitlin et al., 2015).
Transient c-Myc expression can be induced by forcing T–B
cell interactions, leading to reentry into the DZ and stimulation of cell division.
Recently, the role of Foxo1 in the transition from the
LZ-to-DZ program has been explored by two studies, both
indicating that this transcription factor plays a regulatory role
in the formation and maintenance of the GC DZ, as in its
absence there was no DZ in the GC (Dominguez-Sola et
al., 2015; Sander et al., 2015). Notably, in these studies the
overall GC size was intact even in the absence of Foxo1, a
finding somewhat at odds with the aforementioned coupling model between proliferation and the LZ-to-DZ transition. Because the chemokine receptor CXCR4 is one of
the direct physiological Foxo1 targets (Dubrovska et al., 2012;
Dominguez-Sola et al., 2015), the observed DZ defect in
Foxo1-deficient GC B cells has been explained, at least in
© 2017 Inoue et al. This article is distributed under the terms of an Attribution–Noncommercial–Share
Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org
/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
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Results
Hyperexpansion of preGC B cells after Foxo1 ablation
To examine the effects of Foxo1 ablation on antigen-driven
clonal expansion and GC differentiation, we used adoptive
transfer experiments using B1-8hi BCR heavy chain knock-in
B cells, which are specific for the hapten 4-hydroxy-3-nitrophenylacetyl (NP) when combined with Igλ light chains. Before examining the B cell intrinsic biological roles of Foxo1,
we analyzed Foxo1 expression during an immune response.
B1-8hi B cells were transferred into congenically marked
mice and immunized with NP-chicken γ globulin (CGG)/
alum. Foxo1 protein expression level, assessed by intracellular
flow cytometry, was similar or slightly higher in proliferative
CD38+GL7− or CD38+GL7+ B cells than in their naive B
cell counterparts (Fig. 1 A). Compared with parental naive
B cells, the Foxo1 expression level in LZ GC B cells was
higher and the expression level in the DZ GC B cells was
higher than that in LZ GC B cells (Fig. 1 A). This differential
Foxo1 expression between the DZ and LZ GC B cells was
confirmed by Western blot and was also apparent in Foxo1
mRNA levels (Fig. 1 B).
To examine the role of Foxo1 in expansion of preGC
B cells, we co-transferred equal numbers of Foxo1f/f ERT2cre
B1-8hi and Foxo1+/+ ERT2cre B1-8hi B cells into congenically marked mice, which were then immunized with
NP-CGG/alum after tamoxifen treatment (Fig. 1 C). In this
protocol, deletion of Foxo1 was very efficient (Fig. 1 D),
and did not result in any induction of Foxo3 or Foxo4
mRNA (not depicted). Expansion of preGC B1-8hi B cells
(GL7+CD38+IgD+CCR6hi) and their subsequent differentiation toward early GC B cells (IgDloCCR6lo; Schwickert et
al., 2011) were enhanced when Foxo1 was eliminated; control vehicle treatment had essentially no effects. These observations appear to be consistent with the conventional view
that Foxo family transcription factors act as tumor suppressors
(Dansen and Burgering, 2008; Hedrick, 2009).
2

GC maintenance requires Foxo1
The idea that Foxo1 might play a proliferative, rather than
antiproliferative, role during the GC phase has been suggested
by an earlier study showing that GC-derived lymphomas frequently carry mutations in Foxo1 that prevent its inactivation
by Akt (Trinh et al., 2013). Hence, we wished to delete Foxo1
specifically during the GC stage.To do this, we used the same
co-transfer experiments as Fig. 1 C, but used the time course
depicted in Fig. 2 A, because almost all the transferred B1-8hi
B cells in our experimental conditions were already differentiated into GC B cells by day 7. If tamoxifen was administered
at earlier time points, for instance at day 4, deletion of Foxo1
would occur at both preGC and GC stages, possibly complicating interpretation of the data.
Tamoxifen injection resulted in selective diminution of
Foxo1f/f ERT2cre B1-8hi GC B cells; both IgG1− and IgG1+
B1-8hi GC B cells were similarly affected by Foxo1 ablation, whereas control vehicle treatment had no effect (Fig. 2,
B and C). In this protocol, Foxo1 protein and mRNA were
efficiently depleted in GC B cells (labeled as Foxo1f/f in
Fig. 1 B). The similar loss of IgG1− and IgG1+ GC B cells
indicates that deletion of Foxo1 takes place after completion of class switch recombination (CSR) in our protocol,
being different from the previous two studies by using a
Cγ1-cre (Dominguez-Sola et al., 2015; Sander et al., 2015);
indeed, previous studies demonstrate the involvement of
Foxo1 in CSR processes.
To further examine whether Foxo1 ablation affects cell
division, we compared the frequency of Foxo1-deficient and
-proficient LZ GC B cells in the S–G2–M phase of the cell
cycle. By DNA content measurement, Foxo1-deficient LZ
GC B cells exhibited less proliferation status than control cells
(Fig. 2 D, left), and a similar result was obtained when incorporation of the nucleotide analogue 5-ethynyl-2’-deoxyuridine (EdU) over a 0.5-h period was compared (Fig. 2 D,
right). Hence, we conclude that Foxo1 ablation in GC cells
decelerates cell cycle progression.
We then examined the effects of Foxo1 deletion on DZ/
LZ compartmentalization. Consistent with previous studies
(Dominguez-Sola et al., 2015; Sander et al., 2015), the majority
of the Foxo1-deficient GC B cells were CXCR4lowCD86hi,
reminiscent of LZ cells, although a DZ-like population
(CXCR4int) was to some extent detectable, particularly among
IgG1− cells (Fig. 2 B). The compartmentalization defect was
also confirmed histologically.To do this, we also used co-transfer
experiments (Fig. 2 E). In contrast to control vehicle treatment,
localization of tamoxifen-treated Foxo1f/f ERT2cre B1-8hi GC
cells was largely restricted to the LZ, which was defined by the
presence of the CD35+ follicular dendritic cell (FDC) network.
These results suggest that Foxo1-deficient cells are locked in
the LZ even in a GC where overall DZ/LZ compartmentalization is preserved.Together, deletion of Foxo1 in the GC phase
resulted in GC disruption and defective polarization.
The loss of the DZ compartment in Foxo1-deficient
GC cells was further substantiated by gene expression proRegulation of GC B cell proliferation by Foxo1 | Inoue et al.
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part, by down-regulation of CXCR4. However, functionally, the Foxo1-deficient GC B cells appear to be more severely affected than in the CXCR4 knockout (Bannard et al.,
2013). For instance, down-regulation of CD86 occurred in
both Cxcr4−/− and wild-type GC B cells, whereas this regulation was perturbed in Foxo1-deficient GC B cells.These data
imply that the loss of CXCR4 expression is necessary but not
sufficient to account for the defective DZ program resulting
from Foxo1 ablation, prompting us to investigate how Foxo1
participates in the transition from the LZ to the DZ program.
Here, we report that, in addition to CXCR4, Foxo1
participates in up-regulation of the transcription factor BATF.
BATF was transiently expressed in a small fraction of LZ GC
cells, and depletion of BATF, like that of Foxo1, led to the GC
disruption. Hence, our results suggest that Foxo1 controls not
only GC polarization, but also GC proliferation, at least in
part, through mediating BATF expression, together contributing to the transition from the LZ to DZ program.

Downloaded from jem.rupress.org on August 29, 2017

Figure 1. Hyperexpansion of preGC B cells with Foxo1 ablation. (A) Left, flow cytometry of intracellular Foxo1 protein expression in naive B cells
at day 0 (CD45.1+B220+NP+CD38+), activated B cells on day 4 (CD45.1+B220+NP+CD38+GL7− or CD45.1+B220+NP+CD38+GL7+), LZ (CD45.1+B220+NP+CD38−CD86hiCXCR4lo), and DZ (CD45.1+B220+NP+CD38−CD86loCXCR4hi) GC B cells on day 10. Wild-type mice were transferred with B1-8hi CD45.1+
B cells and then immunized i.p. with NP-CGG/alum on day 0. Foxo1 KO staining controls (gray histograms) were prepared as previously described in Figs.
1 C and 2 A. (right) Histograms indicating the geometric mean fluorescence intensity (gMFI) of each population. n = 4 biological replicates. (B) Analysis of
Foxo1 protein and mRNA expression in DZ and LZ GC B cells by Western blot (top) and real-time qPCR (bottom). Foxo1-proficient LZ, DZ, and Foxo1-deficient GC B cells were sorted from mice prepared as described in Fig. 2 A. Actin, loading control. n = 3 biological replicates. (C, top) Schematic illustration of
JEM
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clonal BCR transgenic B cells might enhance the activation
kinetics, which in turn makes more differences particularly in
the competitive settings.
Antigen presentation is inhibited
As GC B cell proliferation is only marginally affected in
Cxcr4−/− mice (Bannard et al., 2013), the aforementioned
findings suggest that, in addition to regulating access into the
anatomical DZ, Foxo1 utilizes other mechanisms, thereby
regulating the transition from the LZ-to-DZ program. According to the current model (Allen et al., 2007; Victora et
al., 2010; Liu et al., 2015), the LZ-to-DZ transition is thought
to be regulated by two consecutive processes; first, the BCR
on LZ B cells functions as an endocytic receptor that shuttles
antigen into the MHC-II pathway for processing and presentation to TFH cells; second, the antigen-specific TFH cells
activated by cognate interaction with the LZ B cells in turn
provide them with T cell help, driving their transition to the
DZ program. Hence, we reasoned that Foxo1 might participate in these two processes.
Before addressing whether the first processes are affected by Foxo1 ablation, we analyzed receptors relevant to
this process and found that expression of BCR and Igβ in
Foxo1-deficient GC cells was lower compared with control
cells (Fig. 5 A). Then, to examine the antigen presentation
activity on GC B cells to TFH cells, we generated a chemical conjugate of NP and recombinant Eα-GFP, which contains the Eα peptide from the I-E molecule (pEα) fused GFP
(Pape et al., 2007). This reagent allows for quantification of
the amount of peptide MHC class II (pMHC-II) presentation. The pMHC-II can be monitored with the Y-Ae monoclonal antibody, which is specific for pEα–I-Ab complexes
(Murphy et al., 1992).
Although we detected antigen capture and pMHC-II
on activated B1-8hi B cells at the preGC stage after NP-EαGFP/alum immunization, neither could be detected on GC
B cells (unpublished data). The most likely explanation for
this is that the antigen availability in the microenvironments
of the GC is very limited, thereby making it undetectable in
vivo by our experimental system. Therefore, in the case of
GC B cells, we performed ex vivo experiments. As shown in
Fig. 5 B, when antigen was provided, Foxo1-deficient B1-8hi
LZ GC B cells were able to present pMHC-II lesser extent
than control cells; both population of pMHC-II+ cells and
their expression levels were low. Next, to ask the question of
why mutant GC B cells possess the low antigen presentation
activity, we delivered the Eα-GFP antigen to GC B cells in a
surrogate manner. For this purpose, instead of targeting to the

the experimental protocol. (bottom left) Flow cytometry of NP-specific donor B cells (CD45.1+B220+NP+). (bottom right) Histograms representing the cell
number of preGC (Donor B220+NP+GL7+CD38+IgD+CCR6hi) and early GC (Donor B220+NP+IgDloCCR6lo) B cells in 106 splenocytes. n = 3 biological replicates.
(D) Real-time qPCR analysis of Foxo1 mRNA expression in Foxo1+/+ERT2cre B1-8hi and Foxo1f/f ERT2cre B1-8hi preGC B cells. Error bars represent SD. Data
are representative of three (A) or two (B and C) independent experiments, and from one experiment with three biological replicates (D). *, P < 0.05; **, P <
0.01; ***, P < 0.001; unpaired Student’s t test (A, B, and D) and paired Student’s t test (C).
4
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file analysis. We prepared mRNA from Foxo1+/+ ERT2cre
B1-8hi DZ and LZ GC B cells and from Foxo1f/f ERT2cre
B1-8hi total GC B cells after tamoxifen treatment at day 12
(Fig. 2 A), and performed transcriptome analysis by RNAseq. A hierarchical clustering analysis indicated that the
Foxo1-deficient GC B cells are more similar to normal LZ
than DZ B cells; the mutant GC profile exhibited a significant absence of gene signatures associated with the DZ program (Fig. 2 F). Hence, our results demonstrate that Foxo1
directly or indirectly controls a major part of the program that
distinguishes DZ from LZ GC B cells. However, when compared with normal LZ GC B cells, some differences were also
noted in the Foxo1-deficient GC B cells. Indeed, gene set
enrichment analysis (Foxo1-deficient GC B cells versus control LZ GC B cells) indicated that the Foxo1-deficient cells
were more weakly imprinted with the signatures of CD40
and BCR signaling (Fig. 2 G).
When Foxo1+/+ ERT2cre B1-8hi and Foxo1f/f ERT2cre
hi
B1-8 B cells were individually transferred (Fig. 3 A), instead
of co-transferred, the similar compartmentalization defect
was observed (Fig. 3 B). The proliferation defect was also observed in the individual transfer experiments, but the defective
extent in the absence of Foxo1 was relatively small, compared
with co-transfer experiments (Fig. 3, C and D). Hence, we
conclude that Foxo1 deletion directly causes the proliferative
changes, although, in the aforementioned mixed B cell chimera experimental settings, cell competition takes place.
Our conclusion that the number of Foxo1-deficient GC
B cells is decreased differs from previous studies demonstrating that the GC size is unchanged in the absence of Foxo1
(Dominguez-Sola et al., 2015; Sander et al., 2015). As these
studies analyzed polyclonal GC responses, we reasoned that
the polyclonal versus our monoclonal system might cause
such differences. To test this possibility, we co-transferred
equal numbers of Foxo1f/f ERT2cre and Foxo1+/+ ERT2cre
donor B cells into congenically marked mice and immunized
them with sheep RBCs (SRBCs). Foxo1 was then deleted
as depicted in Fig. 4 A and, overall, both GC maintenance
and GC compartmentalization were decreased by the loss of
Foxo1 (Fig. 4 B). However, compared with the aforementioned results using B1-8hi B cells, the decrease in polyclonal
Foxo1-deficient GC B cell numbers was relatively small.
Given the hyperexpansion of B cells caused by deletion of
Foxo1 at the preGC stage, one possibility is that, because of
the asynchrony of the polyclonal immune responses, some activated B cells might still have been at the preGC stage when
Foxo1 was deleted (Fig. 4 A), thereby diluting the effects by
GC-specific deletion of Foxo1. It is also possible that mono-
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Figure 2. Foxo1 is required for GC maintenance. (A) Schematic illustration of the experimental protocol for B–D, F, and G. (B) Flow cytometry of
NP-specific donor B cells (CD45.1+B220+NP+). (C) Histograms representing the number of donor IgG1− GC B cells (CD45.1+B220+NP+CD38−IgG1−) and IgG1+
GC B cells (CD45.1+B220+NP+CD38−IgG1+) in 106 splenocytes (left), and the ratio of DZ:LZ cells (right). n = 3 biological replicates. (D, left) DNA content
measurement of Foxo1+/+ and Foxo1f/f LZ GC B cells assessed by 7-AAD staining. n = 5 and 3 biological replicates for tamoxifen and vehicle treatment,
respectively. (right) Proliferation status of Foxo1+/+ and Foxo1f/f LZ GC B cells assessed by EdU incorporation 30 min after an EdU injection. n = 3 biological
replicates. (E) Immunohistochemical analysis. (top) Schematic illustration of the experimental protocol. (bottom left) Representative images of immunofluorescence microscopy of spleen sections showing expression of CD45.1 (Foxo1f/f-derived donor cells), CD35 (FDC network), and IgD (follicular B cells). DZ and
LZ defined by the presence of CD35+ FDCs are surrounded by dashed lines. Bars, 100 µm. (bottom right) Quantification of relative CD45.1 signal intensity
JEM
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Upon access to T cell help, Foxo1-deficient GC cells
have a proliferation defect
We then specifically examined the second process, namely
Foxo1 involvement in the transition from the LZ to the DZ
state after receipt of T cell help. To address this issue, we
adopted an in vivo approach to enforce T cell–B cell interactions by using a T cell antigen (OVA) fused to anti-DEC205
antibody (anti–DEC-OVA; Bonifaz et al., 2002). As shown
in Fig. 6 A, after co-transferring of Foxo1+/+ ERT2cre

B1-8hi and Foxo1f/f ERT2cre B1-8hi B cells, the recipient
mice were immunized with NP-OVA.When stimulated with
anti-DEC-OVA after tamoxifen treatment, Foxo1+/+ but not
Foxo1-deficient GC B cells showed a burst of proliferation;
control vehicle treatment did not induce such differential responses. Thus, we conclude that, even after they receive sufficient T cell help, Foxo1-defcient GC B cells cannot induce
the normal proliferation program.
Consistently, the mutation load in a 570 bp intronic region downstream of JH4 exon of the Igh locus was lower
in the Foxo1-deficient LZ GC B cells compared with the
controls (Fig. 6 B). Therefore, efficient SHM requires Foxo1.
Polh, Lig4, Dnase1, and Aicda genes are involved in SHM and
their transcripts are abundant in the DZ B cells (Victora et
al., 2012). Compared with Foxo1-proficient LZ GC B cells,
all had higher mRNA expression levels in Foxo1-deficient
GC B cells, whereas their levels did not reach those in wildtype DZ GC B cells, except Aicda (Fig. 6 C, left). Despite
the similar mRNA levels of Aicda between Foxo1-deficient
GC B cells and Foxo1-proficient DZ GC B cells, its protein
expression in the mutant cells did not reach that in wildtype DZ GC B cells (Fig. 6 C, right). Thus, key enzymes
involved in SHM were up-regulated, to some extents, even
in the absence of Foxo1, but not corresponding to the level
in wild-type DZ GC cells.
T cell help triggers BATF in a Foxo1-dependent manner
and is required for GC maintenance
Having demonstrated the importance of Foxo1 in regulating
the GC B cell proliferation program upon receipt of T cell
help, we wished to address how Foxo1 exerts this function.
To do this, we first examined the expression of CD40 and
IL-21R, critical receptors for receiving T cell help (Victora
and Nussenzweig, 2012), on Foxo1-deficient B1-8hi LZ GC
B cells. Expression of CD40 was similar, but that of IL-21R
was somewhat lower in Foxo1-deficient LZ GC B cells compared with control cells (Fig. 5 A). To examine whether the
decreased expression of IL-21R affects the proliferation program of GC B cells, we generated bone marrow chimeras
that lack IL-21R on B cells by reconstituting mice with a
mixture of bone marrow cells from μMT and Il21r+/− mice,
and immunized them with NP-CGG/alum. Despite twofold lower expression of IL-21R on Il21r+/− LZ GC B cells,
the number of GC B cells was unaffected (unpublished data).
Moreover, IL-21R expression by Foxo1-deficient LZ GC
B cells was higher than that of IL-21R haploinsufficient cells
(unpublished data).Thus, the expression level of key receptors

in the DZ compared with that in the LZ. Each symbol represents a single GC, and red bars indicate the mean. n = 43 (tamoxifen) and 40 (vehicle) GC pooled
from three animals. (F) Hierarchical clustering of the gene expression profiles of Foxo1+/+ DZ, Foxo1f/f GC, and Foxo1+/+ LZ B cells using genes differentially
expressed (more than twofold) between Foxo1+/+ DZ and Foxo1+/+ LZ B cells (normalized log2 values based on RNA-seq analysis). n = 3 biological replicates.
(G) Gene set enrichment analysis showing the enrichment for genes up-regulated after ligation of CD40 (top) and BCR (bottom) compared of Foxo1+/+ LZ
B cells with Foxo1f/f GC B cells. Error bars represent SD. Data are representative of three (B and C) or two independent experiments (D and E) and from one
experiment (F and G). **, P < 0.01; ***, P < 0.001; unpaired Student’s t test (E) and paired Student’s t test (C and D).
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BCR, we used DEC205. DEC205 is a cell surface receptor,
which was expressed to similar extents between wild-type and
Foxo1-deficient LZ GC B cells (unpublished data). Eα-GFP
was fused to an antibody specific to DEC205 (anti–DECEα-GFP). Upon provision of anti–DEC-Eα-GFP, control
and Foxo1-deficient B1-8hi LZ GC B cells showed similar
presentation of the pMHC-II complex on the cell surface
(Fig. 5 C), indicating that the antigen presentation machinery,
itself, operates similarly in control and Foxo1-deficient GC
B cells. Collectively, the defective antigen presentation activity in Foxo1-deficient GC B cells is most likely explained by
the low level of BCR expression on them.
Because CD19 is known to act as a BCR co-receptor, we wondered whether the decreased CD19 expression
(Fig. 5 A) might affect antigen presentation activity. To examine this possibility, we immunized Cd19cre/+ mice, because
Cd19cre/+ mice retain only one functional Cd19 allele (Rickert et al., 1997). The ex vivo antigen presentation activity of
the LZ GC B cells was unchanged by haploinsufficiency of
CD19 (unpublished data).
Because activation of GC TFH cells requires pMHC-II
on LZ GC B cells, the aforementioned observations predict
that ablation of Foxo1 in GC B cells would render the GC
TFH cells less active in vivo. To test this prediction, after transferring OVA-specific TCR transgenic (OT-II) CD4+ T cells
together with Foxo1f/f ERT2cre B1-8hi or Foxo1+/+ ERT2cre
B1-8hi B cells, we immunized the mice with NP-OVA and
deleted Foxo1 as depicted in Fig. 5 D. 3 d after Foxo1 ablation in GC B cells, both the GC TFH cell numbers and production of IL-21 were decreased. These results suggest that
Foxo1 contributes to antigen presentation by GC B cells and,
subsequently, to activation of GC TFH cells.
In addition to this defective antigen presentation
on Foxo1-deficient LZ GC B cells, the lower expression
of CD86 in the mutant cells, albeit being a small change
(Fig. 5 A), might also be involved in subsequent defective
activation of GC TFH cells.

Figure 3. Assessment of Foxo1 requirement
for GC maintenance and proliferation in single
transfer experiments. (A) Schematic illustration of
the experimental protocol. (B) Flow cytometry of NPspecific donor B cells (CD45.1+B220+NP+). (C) Histograms representing the number of donor IgG1−
GC B cells (CD45.1+B220+NP+CD38−IgG1−) and IgG1+
GC B cells (CD45.1+B220+NP+CD38−IgG1+) in 106 splenocytes (left), and the ratio of DZ:LZ cells (right). n = 5
biological replicates. (D) Proliferation status of
Foxo1+/+ and Foxo1f/f LZ GC B cells assessed by EdU
incorporation 30 min after an EdU injection. n = 3 biological replicates. (E) Analysis of Batf mRNA expression
in Foxo1+/+ DZ, LZ, and Foxo1f/f GC B cells by real-time
qPCR. n = 3 biological replicates. Error bars represent SD. Data are representative of three (B and C) or
two independent experiments (D and E). **, P < 0.01;
***, P < 0.001; unpaired Student’s t test.
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for receiving T cell help appears not to be solely responsible
for the defective proliferation in Foxo1-deficient GC B cells.
Previous studies have shown that transient c-Myc expression only in the LZ is induced by forcing T–B cell interactions and is required for stimulating cell division (Calado et
al., 2012; Dominguez-Sola et al., 2012). We thus hypothesized
that such cell division-related key transcription factors might
exist in the LZ GC B cells, induced by T cell help in a Foxo1dependent manner. Among transcription factors differentially
expressed between LZ and DZ GC B cells (Victora et al., 2012),
c-Myc, Egr2, Egr3, BATF, and Foxp1 were significantly downregulated and Lmo2 was up-regulated in Foxo1-deficient
JEM

B1-8hi GC B cells (Fig. 7 A).A previous study demonstrated that
transgenic expression of FoxP1 leads to a significant decrease in
GC B cells (Sagardoy et al., 2013). In addition, Egr2 and Egr3
have been shown to be negative regulators of T cell activation
(Safford et al., 2005; Zheng et al., 2012), and Lmo2 has been
suggested as a proto-oncogene in T cell acute lymphoblastic
leukemia and in other type of cancers (Chambers and Rabbitts,
2015). Based on these observations, involvement of Egr2, Egr3,
Foxp1, and Lmo2 in GC proliferation in a Foxo1-dependent
manner appeared to be somewhat unlikely. Because c-Myc was
already well characterized (Calado et al., 2012; Dominguez-Sola
et al., 2012), we focused our analysis here on BATF.
7

Figure 4. GC phenotype with Foxo1 ablation
during a polyclonal immune response. (A) Schematic representation of the experimental protocol.
Because entering the GC in the polyclonal stimulation was a little earlier than the monoclonal condition
(Fig. 2 A), we treated mice with tamoxifen on day 6,
7, and 8, and analyzed on day 11. (B, top) Flow cytometry of donor B cells (B220+CD45.1−CD45.2+ and
B220+CD45.1+CD45.2−). (bottom left) Percentage of
each donor in total donor GC B cells (CD45.1−CD45.2+
or CD45.1+CD45.2−B220+GL7+CD38−). (bottom right)
Ratio of DZ:LZ cells. n = 5 biological replicates. Error
bars represent SD. *, P < 0.05; ***, P < 0.001; paired
Student’s t test. Data are representative of two
independent experiments.
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Fig. 8 A; both Batff/f ERT2cre B1-8hi and Batf+/+ ERT2cre
B1-8hi B cells were co-transferred into congenically marked
mice, which were immunized with NP-CGG, and then
treated with tamoxifen to delete Batf in GC B cells (Fig. 8 D).
As shown in Fig. 8 B, in contrast to control vehicle treatment,
tamoxifen injection resulted in a selective decrease of Batff/f
ERT2cre B1-8hi GC B cells; the decrease was more prominent in the DZ. Furthermore, when EdU was incorporated
over 0.5 h, BATF-deficient LZ GC B cells showed less proliferation than control cells (Fig. 8 C). Thus, BATF is upregulated by T cell help in a Foxo1-dependent manner, and is
required for GC B cell proliferation.
The aforementioned findings raise the question of
whether Foxo1 ablation-mediated anomalies could be explained by the defective expression of BATF. To explore this
question, we used a retroviral transduction system, allowing
for both inducible expression of BATF and inducible deletion of endogenous Foxo1 (Fig. 8 E). Retrovirus-infected
donor B cells were transferred into congenically marked
mice, which were immunized and then treated with tamoxifen. Transduction with BATF was monitored by GFP, and
deletion of Foxo1 in Foxo1f/f donor B cells was confirmed
by RT-qPCR (unpublished data). Foxo1-proficient cells
transduced by BATF exhibited not significant expansion of
Regulation of GC B cell proliferation by Foxo1 | Inoue et al.

Downloaded from jem.rupress.org on August 29, 2017

Indeed, provision of in vivo T cell help by injection
of anti–DEC-OVA induced up-regulation of Batf mRNA
in B1-8hi GC LZ B cells, and this was dependent on Foxo1
(Figs. 3 E and 7 B). Conversely, inhibition of the T-B interactions in vivo by CD40 blockade decreased Batf expression
(Fig. 7 C). Next, we wondered whether BATF, like c-Myc,
is dominantly expressed in a small fraction of LZ GC B cells
and, if so, whether this small BATFhi LZ fraction is more
actively cycling than the BATFlo LZ cells. After NP-CGG
immunization of wild-type mice, BATFhi and BATFlo fractions were present among the LZ GC B cells, as assessed by
intracellular cytometry analysis (Fig. 7 D), and the population
of the BATFhi fraction was increased by anti–DEC-OVA injection (Fig. 7 D). Moreover, the BATFhi cells were more actively cycling (Fig. 7 E). To examine the relationship between
BATFhi cells and c-Myc+ cells in the LZ, we used NP-CGG–
immunized mice harboring c-Myc-GFP (Huang et al., 2008).
According to these staining patterns, c-Myc+ cells were
mainly included in the BATFhi LZ fraction; ∼30% among
BATFhi cells coexpressed c-Myc (Fig. 7 F). BATFhi and BATFlo
LZ fractions expressed similar levels of Foxo1, assessed by intracellular cytometric analysis (Fig. 7 G).
Next, to address the function of BATF in GC maintenance, we used the experimental protocol depicted in
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Figure 5. Decreased antigen presentation of Foxo1-deficient LZ GC B cells. (A, left) Flow cytometry of surface molecules on Foxo1+/+ and Foxo1f/f LZ GC B cells.
Mice were immunized as described in Fig. 2 A, and LZ GC B cells were prepared on day 12. (right) Histograms indicating the gMFI of each population. n = 3 biological
replicates. (B) In vitro antigen presentation assay. Mice were prepared as described in Fig. 3 A. Purified splenic B cells were incubated with NP-Eα-GFP or Eα-GFP for
1 h at 37°C. Antigen-presenting LZ GC B cells were detected by staining the LZ GC B cells (CD45.1+CD138−GL7+CD38−CD86hiCXCR4lo) with Y-Ae antibody. (left) Flow
cytometry of LZ GC B cells; (middle) the percentage of Y-Ae+ (bracketed line in the left) LZ GC B cells; (right) the gMFI of Y-Ae of Y-Ae+ LZ GC B cells. n = 3 biological
replicates. (C) In vitro antigen presentation of Foxo1-deficient LZ GC B cells using αDEC-Eα-GFP. Eα-GFP and αDEC-OVA were used as negative controls. Mice were
prepared as described in Fig. 3 A. (left) Flow cytometry of LZ GC B cells; (right) the percentage of Y-Ae+ (bracketed line in the left) LZ GC B cells. n = 3 biological replicates. (D) Effects of Foxo1 ablation in LZ GC B cells on TFH cell number and cytokine production. (left) Schematic representation of the experimental protocol. Foxo1+/+
ERT2cre B1-8hi CD45.1+CD45.2+ or Foxo1f/f ERT2cre B1-8hi CD45.1+CD45.2+ B cells were co-transferred together with CD4+ T cells from OT-II CD45.1+CD45.2+ mice into
wild-type mice (CD45.1−CD45.2+), which were immunized with NP-OVA/alum i.p. on day 0. Mice were administered tamoxifen p.o. on day 7, 8, and 9, and analyzed on
day 12. (middle) Flow cytometry of OT-II CD4+ T cells (CD45.1+CD4+). (right) The percentage of TFH cells (CD45.1+CD4+CXCR5+PD-1+) among total donor OT-II cells, and
the quantification of Il21 mRNA expression in sorted TFH cells by real-time qPCR. n = 8 biological replicates. Error bars represent SD. Data are representative of three
(A) or two (B–D) independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; unpaired Student’s t test.
JEM
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Figure 6. Foxo1-deficient GC B cells have defects in proliferation and SHM. (A, top) Schematic representation of the experimental protocol. Mice
were injected i.p. with αDEC-OVA on day 10 and analyzed on day 12. Bottom, proliferation status of Foxo1+/+ and Foxo1f/f GC B cells assessed by EdU incorporation 30 min after an EdU injection. n = 4 biological replicates. (B) JH4 intron SHM analysis in control and Foxo1-deficient LZ GC B cells. (top) Schematic
representation of the experimental protocol. Bottom left, the pie charts showing the relative frequency of sequences with 0–5 mutations from mice of each
genotype. n = number of sequences analyzed. (bottom right) Mutation frequencies (number of mutations in a JH4 570 bp intronic region). Red bars indicate
the mean. (C, left) Expression of selected SHM-related genes in Foxo1+/+ LZ, Foxo1f/f GC, and Foxo1+/+ DZ B cells based on RNA-seq analysis. Relative fragments per kilobase of exon per million reads (FPKM) values normalized with Foxo1+/+ LZ cells are shown. For Dnase1, the FPKM value of Foxo1f/f GC B cells
was set as 1. #, undetected. n = 3 biological replicates. (right) Flow cytometry of intracellular AID protein expression in Foxo1+/+ LZ, Foxo1f/f GC, and Foxo1+/+
DZ GC B cells. Gray histogram, control signal in Aicda KO GC B cells, which were prepared from immunized Aicdaf/f ERT2cre mice treated with tamoxifen.
Error bars represent SD. Data are representative of two independent experiments (A and C, right), pooled from two independent animals (B), and from one
experiment with three biological replicates (C, left). *, P < 0.05; paired Student’s t test (A) and Mann-Whitney test (B).
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GC B cells, suggesting that, in these proficient conditions,
BATF is not a limiting factor. Foxo1-deficient cells transduced by empty retrovirus manifested the expansion defect,
as expected, whereas this defect was restored by transduction
of BATF, suggesting that BATF is critical for the effects of
Foxo1 on GC proliferation (Fig. 8 F). Nevertheless, Foxo1
ablation-induced polarization defect could not be restored,
consistent with the previous data that CXCR4 is a direct target of Foxo1 (Dubrovska et al., 2012; Dominguez-Sola et al.,
2015). Thus, the LZ-dominant phenotype induced by BATF
ablation (Fig. 8 B) is likely a result of secondary effects caused
by proliferation anomalies, but not by direct down-regulation
of CXCR4 as observed in Foxo1 ablation.

Figure 7. T cell help triggers BATF expression in a Foxo1-dependent manner. (A) Expression of selected transcription factors in Foxo1+/+
LZ, Foxo1f/f GC, and Foxo1+/+ DZ B cells based on RNA-seq analysis. Relative FPKM values normalized with Foxo1+/+ LZ cells are shown. (B) Realtime qPCR analysis of Batf mRNA in control and Foxo1-deficient LZ GC
B cells after injection of anti–DEC-OVA. Data were normalized with control
cells treated with anti–DEC-CS. n = 3 biological replicates. (C) Real-time
qPCR analysis of Batf mRNA in wild-type LZ GC B cells after injection of
anti-CD40L. n = 4 biological replicates. (D, left) Flow cytometry of intracellular BATF protein expression in LZ and DZ GC B cells. Gray histogram, conJEM

trol signal in Batf KO cells prepared as described in Fig. 8 A. Bracketed lines
indicate the BATFlo and BATFhi populations. (middle left) BATF gMFI of each
population. n = 3 biological replicates. (middle right) Percentage of BATFhi
population. n = 3 biological replicates. (right) Percentage of BATFhi population in the LZ B cells. B1-8hi CD45.1+ B cells were transferred into wild-type
mice (CD45.1−CD45.2+), which were immunized with NP-OVA/alum i.p. on
day 0. Mice were injected i.p. with anti–DEC-OVA or anti–DEC-CS on day
10. CD45.1+B220+NP+ LZ B cells were analyzed 24 h after injection of each
antibody. n = 3 biological replicates. (E, left) Cell cycle analysis of BATFlo
LZ, BATFhi LZ, and DZ GC B cells. (right) The percentage of GC B cells at
different stages of the cell cycle. S, EdU+ 7-AADint; G2/M, EdU− 7-AADhi;
G0/G1, EdU− 7-AADlo. Wild-type mice were immunized with NP-CGG/alum
i.p., followed by injection of EdU on day 10, 30 min before analysis of the LZ
(B220+GL7+CD38−CD86hiCXCR4lo), and DZ (B220+GL7+CD38−CD86loCXCR4hi) GC
B cells. n = 5 biological replicates. (F, left) Flow cytometry of intracellular
BATF and c-Myc-GFP expression in GC B cells of c-Myc-GFP and wild-type
mice. (right) Percentage of c-Myc-GFP+ populations in BATFhi and BATFlo
LZ B cells of c-Myc-GFP mice and total LZ B cells of wild-type B cells. n
= 3 biological replicates. (G) Flow cytometry of intracellular Foxo1 protein expression in BATFhi and BATFlo LZ GC B cells. Gray histogram, control
signal in Foxo1 KO LZ B cells. Error bars represent SD. Data are from one
experiment with three biological replicates (A), or representative of two
independent experiments (B–G). *, P < 0.05; **, P < 0.01; ***, P < 0.001;
unpaired Student’s t test.
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Foxo1 acts in a context-dependent manner
The aforementioned results raised the question of why Foxo1
ablation leads to opposite proliferation outcomes, depending
on whether it occurs in the preGC or GC stage (Fig. 1 C
and 2 B). To gain insight into this point, we performed
BATF deletion experiments at the preGC stage. Expansion
of BATF-deficient B1-8hi B cells was significantly decreased
after tamoxifen treatment (Fig. 9 A), similar to what was observed with BATF deletion at the GC phase. However, effects
of Foxo1 deletion on BATF expression differs between the
preGC and GC stages. As shown in Fig. 9 B, in preGC B cells
BATF was up-regulated in Foxo1-deficient B1-8hi B cells.
A straightforward explanation of these results is that the
mechanisms by which Foxo1 regulates BATF differ between
preGC (inhibitory) and GC (stimulatory) phases, although
the role of BATF in B cell proliferation is similar between
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these two phases. Hence, our data suggest that the regulatory
network operating through Foxo1 is highly context-specific.

Figure 8. BATF is required for GC maintenance. (A) Schematic illustration of the experimental protocol for B–D. (B, top) Flow cytometry of NP-specific
donor B cells (CD45.2+B220+NP+). (bottom left) Histograms showing the donor GC B cell (CD45.2+B220+NP+Fas+CD38−) number in 106 splenocytes. (bottom
right) The ratio of DZ:LZ cells. n = 4 biological replicates. (C) Proliferation status of Batf+/+ and Batff/f LZ GC B cells assessed by EdU incorporation 30 min
after an EdU injection. n = 4 biological replicates. (D) Real-time qPCR analysis of Batf mRNA expression in Batf+/+ERT2cre B1-8hi and Batff/f ERT2cre B1-8hi
GC B cells. n = 4 biological replicates. (E) Schematic illustration of the experimental protocol for F. Note that viral infection efficiencies were comparable
between samples as assessed by GFP+ population (∼15–20%) before transfer. (F, left) Flow cytometry of CD45.1+B220+ cells. (right) Histograms showing the
number of GFP+ GC B cell (CD45.1+B220+GFP+CD38−) in 106 splenocytes. n = 8 (Foxo1+/+) and 10 (Foxo1f/f) biological replicates. Error bars represent SD. Data
are representative of two independent experiments (B and C), from one experiments with three biological replicates (D), representative of four independent
experiments (F, left), and are pooled from four independent experiments (F, right). *, P < 0.05; **, P < 0.01; ***, P < 0.001; paired Student’s t test (B and C)
and unpaired Student’s t test (D and F).
JEM
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Discussion
By focusing on Foxo1 functions in GC B cells, we demonstrate that Foxo1 participates in two consecutive processes occurring in the LZ, antigen presentation to GC TFH cells and
subsequent activation through T cell help, and that through
these mechanisms Foxo1 regulates the GC B cell proliferation
program. The latter conclusion is seemingly inconsistent with
previous studies demonstrating apparently normal expansion
of Foxo1-deficient GC B cells (Dominguez-Sola et al., 2015;
Sander et al., 2015). By ablating Foxo1 before or after GC
establishment, we found that, in contrast to ablation at the
GC stage, hyper-expansion of preGC B cells was induced by
Foxo1 deletion at the preGC stage. Therefore, considering
that class-switching begins at the preGC stage (Toellner et al.,
1998; Shlomchik and Weisel, 2012), it is likely that the previous studies using a Cγ1-cre have led to deletion of Foxo1 in
preGC cells, at least to some extents.The observed phenotype
would thus result from a combination of effects of Foxo1
deletion at preGC and GC cell stages.
GC B cells expressing higher amounts of surface pMHC-II have been thought to receive better quality/quantity
of help from GC TFH cells, thereby contributing to their preferential proliferation. Indeed, it was shown that B cells deficient in the MHC family molecule H2-O, an inhibitor of
peptide loading into MHC-II, outcompete H2-O–sufficient
B cells in mixed knockout and wild-type GCs, even under
conditions in which BCR affinity for NP was equalized
(Draghi and Denzin, 2010). Conversely, Foxo1-deficient GC
B cells with lower levels of surface pMHC-II were less capable of activating cognate GC TFH cells. This could be most
likely caused by down expression of BCR in the absence
of Foxo1. Supporting this possibility, we found that when a
T cell antigen was targeted to DEC205, instead of BCR, on
GC B cells, similar surface pMHC-II presentation was induced between mutant and control GC cells.
How does Foxo1 contribute to proper BCR expression
by LZ GC B cells? Because IgH, and Igα, but not Igβ are expressed to the same extents at the protein level in Foxo1-deficient LZ GC B cells as in controls (unpublished data), the
lower level of Igβ is most likely responsible for the lower
BCR levels on the surface of mutant LZ GC B cells. Indeed,

in developing B cells, the importance of Igβ for the assembly and the cell surface expression of the preBCR has been
documented (Gong and Nussenzweig, 1996; Kurosaki, 2002).
The protein, but not mRNA, level of Igβ was decreased in
Foxo1-deficient GC cells (unpublished data). In this regard,
Itch, one of the HECT family of E3 ligases, was reported to
mediate the constitutive ubiquitinylation of Igβ, and that this
was required for normal sorting through the endocytic pathway (Zhang et al., 2007). Hence, one possibility is that such
ubiquitin-mediated mechanisms might control constitutive
Igβ protein levels in a Foxo1-dependent manner.
By taking a strategy of providing T cell help by targeting a T cell antigen to GC B cells through DEC205, we
could show that even after receipt of sufficient T cell help,
Foxo1-deficient GC B cells cannot induce the normal proliferation program. Thus, in in vivo physiological settings,
the malfunctioning DZ program in the Foxo1-deficient
LZ GC cells is likely to result from two defects, the mutant
B cells receive weaker help from GC TFH cells and are less
capable of responding to it. Therefore, our data are consistent with a model in which T cell help plays a critical role
in the LZ-to-DZ switch.
The DZ is believed to be tightly linked with the cell
cycle; indeed, expression of cell cycle–related genes is increased in the DZ (Victora et al., 2012). Here, B cells in GCs
devoid of the DZ as a result of the absence of Foxo1 manifest
three features; 1) defective proliferation; 2) insufficient elevation of many cell cycle-related genes; and 3) defective induction of c-Myc and BATF, critical regulators for inducing the
cell cycle progression. Because CXCR4 is a target of Foxo1,
Foxo1 controls both access to the anatomical DZ and the
proliferation program, possibly making it the key coupling
molecule between these two DZ functions.
As expected because of defective GC B cell proliferation and defective expression of key enzymes involved in
SHM, SHM is also perturbed in the absence of Foxo1. SHM
and selection are thought to take place in distinct zones,
the DZ and LZ, respectively. This spatial separation has also
been suggested to be important for normal SHM, because
GC B cells deficient in CXCR4 displayed defective SHM,
despite apparently normal cell division. Hence, in the case
of Foxo1-deficient GC B cells, in addition to the aforementioned defect, the inability to physically separate sites of SHM
and selection might also contribute to defective SHM.

BATF belongs to the AP-1 family of transcription
factors that include Fos, Jun, and Atf (Dorsey et al., 1995).
A previous study demonstrates that BATF is required for
GCs (defined by GL7+Fas+ B cells in this study) in a T cell–
but not B cell–dependent manner (Ise et al., 2011). CD38,
rather than Fas, is a better marker to delineate these cells.
Indeed, both GL7+CD38+ (intermediate cells toward mature GL7+CD38− GCs) and GL7+CD38− cells express FAS
to the same extents (Taylor et al., 2012). Here, by using the
GL7+CD38− marker, we showed the requirement for B cell–
dependent BATF in mature GCs; BATF-deficient B cells,
when singly transferred, gave rise to GL7+CD38+, but not
GL7+CD38− GCs (unpublished data).Thus, it is likely that most
of the GL7+Fas+ B cells detected by the previous study could
correspond to GL7+CD38+ cells.
As observed in the previous study (Dominguez-Sola et
al., 2015), we also found that BATF expression is severely reduced in Foxo1-deficient LZ GC B cells. An additional three
lines of evidence allow us to conclude that the GC proliferation defect seen in the absence of Foxo1 is due, at least in
part, to defective up-regulation of BATF. First, BATF is upregulated by enforced T cell help in a Foxo1-dependent
14

manner. Second, ablation of BATF during the GC reaction,
like Foxo1 ablation, led to proliferation defect. Finally, forced
expression of BATF restores the defective GC expansion
induced by Foxo1 ablation. Because BATF lacks a transcriptional activation domain, it acts through its interactions with
other Jun or IRF family members (Murphy et al., 2013).
Probably, not appreciably increase in the GC expansion by
overexpression of BATF in Foxo1-proficient cells could be
explained by requirement for other partners to exert the
BATF action. Despite the importance of BATF, it is clearly
only one of several critical factors underlying the defective
proliferation induced by Foxo1 ablation. For instance, incomplete up-regulation of c-Myc in the absence of Foxo1 also
appears to contribute to.
In regard to regulation of BATF by Foxo1, no significant binding of Foxo1 to Batf locus was observed in human
GC B cells in a previous ChIP-seq analysis (Dominguez-Sola
et al., 2015). Instead, our gene set enrichment analysis showed
that Foxo1-deficient LZ GC B cells were more weakly imprinted by BCR and CD40 signature genes, simply suggesting the involvement of Foxo1 in BCR and CD40 signaling.
Moreover, BATFhi expression is restricted to a small fraction
Regulation of GC B cell proliferation by Foxo1 | Inoue et al.
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Figure 9. BATF is required for preGC B cell expansion and is up-regulated in Foxo1-deficient preGC B cells. (A, top) Schematic illustration of the
experimental protocol. Batf+/+ ERT2cre B1-8hi (CD45.1+CD45.2+) and Batff/f ERT2cre B1-8hi (CD45.1−CD45.2+) B cells were co-transferred into recipient mice
(CD45.1+CD45.2−), which were immunized with NP-CGG/alum i.p. on day 0. Mice were administered tamoxifen or vehicle p.o. for 3 d and analyzed on day
4. (bottom left) Flow cytometry of NP-specific donor B cells (CD45.2+B220+NP+). (bottom right) Histograms showing the cell number of total donor cells
(CD45.2+NP+B220+) and early GC B cells (CD45.2+NP+B220+GL7+CD38−) in 106 splenocytes. n = 4 biological replicates. (B) Real-time qPCR analysis of Batf
mRNA expression in control and Foxo1-deficient B1-8hi preGC (donor B220+NP+CD38+GL7+) and LZ GC B cells (donor B220+NP+GL7+CD38−CD86hiCXCR4lo).
preGC B cells and LZ GC B cells were prepared from mice as described in Fig. 1 C and Fig. 2 A, respectively. n = 3 biological replicates. Error bars represent
SD. Data are representative of three (A) or two independent experiments (B). *, P < 0.05; **, P < 0.01; ***, P < 0.001; paired Student’s t test (A) and unpaired Student’s t test (B).

Materials and methods
Mice
Foxo1f/f (Paik et al., 2007), B1-8hi (Shih et al., 2002), c-MycGFP (Huang et al., 2008), and Cd19cre/+ (Rickert et al., 1997)
mice were provided by R.A. DePinho (The University of Texas
MD Anderson Cancer Center, Houston, TX), M.C. Nussenzweig (Tha Rockefeller University, New York, NY), B.P. Sleckman (Washington University School of Medicine, St. Louis,
MO), and K. Rajewsky (Max Delbruck Center for Molecular
Medicine in the Helmholtz Alliance, Berlin-Buch, Germany),
respectively. Rosa26-ERT2cre mice were obtained from
Taconic Farms. Il21+/− and OT-II mice were obtained from The
Jackson Laboratory. Batff/f (Kuwahara et al., 2016) and μMT
(Kitamura et al., 1991) mice were described previously. Aicdaf/f mice were generated by homologous recombination using
Bruce4 ES cells so that exons 2 and 3 were flanked with two
loxp sites. Positive ES clones were used for microinjection to
obtain chimeric mice, which were then crossed with C57BL/6
mice to obtain germline transmitted animals. C57BL/6 mice
were purchased from CLEA Japan. Sex-matched 8–15-wk-old
mice were used for all the experiments. For the experiments
with mixed bone marrow chimeras, C57BL/6 mice were lethally irradiated (8.5 Gy) and reconstituted with a mixed inoculum of 80% μMT and 20% Il21+/− bone marrow cells at least
8 wk before immunization. All mice were bred and maintained
under specific pathogen–free conditions and all animal experiments were performed under the institutional guidelines of the
Institute of Physical and Chemical Research Research Institute, Osaka University, and Washington University in St. Louis.
Immunization
Mice were immunized with 100 µg of NP-CGG or NPOVA precipitated with Imject alum (Thermo Fisher ScienJEM

tific), or with ∼5 × 108 SRBCs by i.p. injection. The deletion
of the loxP-flanked allele of the target genes was induced by
oral administration (p.o.) of 2 mg tamoxifen (Sigma-Aldrich)
in sunflower oil (Sigma-Aldrich) once per day for 3 d.
Flow cytometry analysis
Single-cell suspensions of splenocytes were prepared and analyzed as previously described (Inoue et al., 2015). Anti-B220
(RA3-6B2), IgG1 (A85-1), CD138 (281–2), CD45.2 (104),
IgM[a] (DS-1), PD-1 (J43), CXCR5 (2G8), CD19 (1D3), and
Fas (Jo2) were purchased from BD. Anti-GL7 (GL7), CXCR4
(2B11), CD4 (GK1.5), Igα (HM47), MHC-II (M5/114.15.2),
CD16/32 (93), ICOSL (HK5.3), CD80 (16-10A1), IgD (1126c), and AID (mAID-2) were purchased from eBioscience.
Anti-CD38 (90), CD86 (GL-1), CD45.1 (A20), Igβ (HM7912), CD22 (OX-97), CD40 (3/23), CD83 (Michel-19),
CCR6 (29-2L17), and Brilliant Violet 510 Streptavidin were
purchased from BioLegend. For staining with an isotype
control for CD86 (Fig. 4 C), we used anti-CD83 instead of
anti-CD86 for gating LZ GC B cells. For intracellular staining, the cells were fixed and permeabilized using a Foxp3
staining kit (eBioscience) for anti-Foxo1 (C29H4; Cell Signaling Technology) staining, or a True-Nuclear Transcription Factor Buffer Set (BioLegend) for anti-BATF (D7C5;
Cell Signaling Technology) staining. Cells were incubated
with first antibody, and then incubated with Alexa Fluor
488– or Alexa Fluor 647–conjugated anti–rabbit antibody
(Thermo Fisher Scientific). APC-conjugated NP was prepared as described previously (Shinnakasu et al., 2016). For
EdU incorporation assays, mice were injected i.p. with 1 mg
EdU (Thermo Fisher Scientific) in PBS and sacrificed 30
min later. Splenocytes were surface-stained, and then EdUincorporated cells were identified using a Click-iT Plus EdU
Flow Cytometry Assay kit (Thermo Fisher Scientific) according to the manufacturer’s instructions.
Adoptive transfers
Adoptive transfer experiments were performed as described
previously (Shinnakasu et al., 2016). In brief, splenic B cells
were purified by magnetic cell depletion using anti-CD43
MicroBeads and the AutoMACS system (Miltenyi Biotec). For B1-8hi B cell transfer experiments, purified B1-8hi
B cells containing 105 NP-binders (a 1:1 mixture of 5 × 104
NP-binders for co-transfer experiments) were transferred
i.v. into recipient mice. For B cell co-transfer experiments in
Figs. 4 and 6 B, 107 purified B cells (a 1:1 mixture of 5 × 106
B cells) were used for donor.
SHM sequence analysis of the JH4 intron
Mice were co-transferred with Foxo1+/+ ERT2cre
(CD45.1+CD45.2–) and Foxo1f/f ERT2cre (CD45.1+CD45.2+)
B cells, and immunized with NP-CGG/alum on day 0. On
day 7, 8, and 9, mice were orally administered tamoxifen. On
day 14, LZ GC B cells from each donor were sorted (∼103
cells) for genomic DNA purification. JH4 intron sequences
15
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of LZ GC B cells, which also express c-Myc. The c-Myc+
GC B cell fraction has been reported to be enriched for high
affinity BCRs, which are required for strong T cell help. Taking these observations together, we speculate that, rather than
direct transcriptional regulation of BATF by Foxo1, Foxo1
is required for generating strong BCR and CD40 signaling
by modulating the expression of such receptors, associated
signaling molecules, and/or transcriptional regulators, which
in turn, leads to up-regulation of BATF.
Considering the previous conventional idea that Foxo1
acts as a tumor suppressor, it has been puzzling why GCderived diffuse large B cell lymphomas frequently carry mutations in Foxo1 that prevent its inactivation by Akt (Trinh et
al., 2013). A large number of Foxo1-bound sites was reported
to co-localize with sites bound by Bcl6, suggesting that Foxo1
and Bcl6 cooperate in the transcriptional modulation of a
subset of targets (Dominguez-Sola et al., 2015). Such modulation of Foxo1 activity by Bcl6 likely makes Foxo1 exert an
unconventional proliferative role specifically in GC B cells,
providing an explanation for the generation of GC-derived
lymphomas by active Foxo1.

were amplified using Ex Taq DNA polymerase (Takara
Bio Inc.) with primers 5′-TCCTAGGAACCAACTTAA
GAGT-3′ and 5′-TGGAGTTTTCTGAGCATTGCAG3′ (Gitlin et al., 2014). PCR products were subcloned into
the pGEM-T vector (Promega) and single clones (∼50
per mouse) were sequenced.

RNA-seq analysis
Wild-type mice were co-transferred with Foxo1+/+ ERT2cre
B1-8hi (CD45.1+CD45.2−) and Foxo1f/f ERT2cre B1-8hi
(CD45.1+CD45.2+) B cells, and immunized with NP-CGG
precipitated in alum on day 0. On day 7, 8, and 9, mice
were orally administered tamoxifen. On day 12, Foxo1+/+
LZ (CD45.1+CD45.2−B220+NP+GL7+CD38−CD86hiCXCR4lo) and DZ GC B cells (CD45.1+CD45.2–B220+NP+GL7+CD38−CD86loCXCR4hi), and Foxo1f/f GC B cells
(CD45.1+CD45.2−B220+NP+GL7+CD38−) were sorted for
RNA preparation. Three biological replicates were used in
each genotype. Construction of DNA libraries for RNAseq and sequencing were performed as described previously
(Shinnakasu et al., 2016). In brief, the DNA library was constructed using an NEBNext Ultra RNA Library Prep kit for
Illumina (NEB) from total RNA purified from ∼104 sorted
cells. RNA-sequencing was performed on a HiSeq 1500 sequencer (Illumina) in a 49-bp single-end read mode. Gene
set enrichment analysis was performed using GSEA software
v2.2.2 (Subramanian et al., 2005). The lists of gene signature
of up-regulated genes by CD40 and BCR stimulation for
gene set enrichment analysis were previously described (Victora et al., 2010; Shinnakasu et al., 2016). The RNA-seq data
are available at Gene Expression Omnibus database under
accession no. GSE93554.
Anti–DEC-OVA and anti-CD40L treatment
For anti–DEC-OVA treatment, wild-type mice were co-transferred with Foxo1+/+ ERT2cre B1-8hi (CD45.1+CD45.2−)
and Foxo1f/f ERT2cre B1-8hi (CD45.1+CD45.2+) B cells, and
immunized with NP-OVA precipitated in alum on day 0.
On day 7, 8, and 9, mice were orally administered tamoxifen. The mice were injected i.p. with 10 µg anti–DEC-OVA
(Victora et al., 2010) on day 10, and sacrificed for analysis on
16

Immunohistochemistry
Spleens were fixed in 4% paraformaldehyde for 2 h on ice,
and then incubated in PBS overnight at 4°C. Next, the
spleens were embedded in Tissue-Tek OCT Compound
(Sakura Finetek) and frozen at –80°C. 8-µm-thick sections
were mounted on glass slides and blocked with CAS-Block
(Invitrogen) for 10 min at room temperature. The samples
were first stained with biotin anti-CD45.1, followed by incubation with Alexa Fluor 546 streptavidin (Thermo Fisher
Scientific), eFluor 450 anti-IgD (11-26c; eBioscience), and
APC anti-CD21/35 (7G6; BD). Images were acquired using
a Fluoview FV10i confocal microscope system (Olympus).
CD45.1 signal intensity was quantified using ImageJ software
(National Institutes of Health), by which relative mean intensity values of CD45.1 signals in the DZ compared with those
in the LZ was calculated.
Western blot
Sample preparation and Western blot were performed as described previously (Inoue et al., 2015). Immunoblotting was
performed using anti-Foxo1 (C29H4; Cell Signaling Technology) and anti–β-actin (C-11; Santa Cruz Biotechnology, Inc.).
qPCR analysis
Real-time qPCR was performed as described previously (Inoue
et al., 2015). Actb mRNA levels were used for normalization.
The following primers were used for qPCR analysis: Foxo1
forward, 5′-AAGAGCGTGCCCTACTTCAA-3′; Foxo1 reverse, 5′-CTGTTGTTGTCCATGGACGC-3′; Foxo3 forward, 5′-AGGATAAGGGCGACAGCAAC-3′; Foxo3 reverse,
5′-CCCGTGCCTTCATTCTGA-3′;Foxo4 forward,5′-CTT
CCTCGACCAGACCTCG-3′; Foxo4 reverse, 5′-ACAGGA
TCGGTTCGGAGTGT-3′; Il21 forward, 5′-TCAGCTCCA
CAAGATGTAAAGGG-3′; Il21 reverse, 5′-GGGCCACGA
GGTCAATGAT-3′; Batf forward, 5′-GTTCTGTTTCTC
CAGGTCC-3′; Batf reverse, 5′-GAAGAATCGCATCGC
TGC-3′; Actb forward, 5′-CCGCCACCAGTTCGCCATG3′; Actb reverse, 5′-TACAGCCCGGGGAGCATCGT-3′.
Inducible retroviral expression of BATF in vivo
To inducibly express BATF in Foxo1-deficient B cells in
vivo, Foxo1+/+ ERT2cre B1-8hi (CD45.1+CD45.2+) or Foxo1f/f ERT2cre B1-8hi (CD45.1+CD45.2+) mice were immunized i.p. with 50 µg of NP-Ficoll in PBS. 6 h later, splenic
B cells were purified from these mice and cultured with 2
µg/ml anti-CD40 for 18 h in vitro. Cells were then retroRegulation of GC B cell proliferation by Foxo1 | Inoue et al.
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In vitro antigen presentation assay
Purified splenic B cells (∼2.5 × 106 cells) were incubated
with 1 µg/ml NP-Eα-GFP, Eα-GFP (Itano et al., 2003;
Pape et al., 2007), αDEC-OVA (Boscardin et al., 2006), or
αDEC-Eα-GFP for 1 h at 37°C. Surface pMHC-II was detected by staining the NP-specific LZ GC B cells with biotin-conjugated Y-Ae antibody (eBioscience). For generation
of αDEC-Eα-GFP, cDNA encoding Eα-GFP was inserted
in frame with the carboxyl terminus of the heavy chain of
mouse αDEC-205 (Boscardin et al., 2006), and the fusion
antibody was expressed using Expi293 Expression System
(Thermo Fisher Scientific) and purified on HiTrap Protein G
HP column (GE Healthcare).

day 12. As a control, we used a chimeric antibody in which
anti-DEC205 was fused to an irrelevant antigen, Plasmodium
falciparum circumsporozoite protein (anti–DEC-CS). For
anti-CD40L treatment, wild-type mice were immunized i.p.
with NP-CGG in alum on day 0. The mice were injected i.p.
with 250 µg IgG1 anti-CD40L (MR1; Bio X Cell) or control
hamster IgG (Innovative Research) on day 7 and sacrificed
for analysis 12 h later.

virally transduced with an inducible BATF expression cassette by spin infection (800 g, 90 min, 25°C) with polybrene
(8 µg/ml, Millipore) and virus supernatant produced in
PLAT-E cells. The retroviral vector was constructed by inserting loxp-flanked human CD2, mouse BATF cDNA, and
IRES-EGFP into pMYs vector (Fig. 8 E). 3 h after infection, 106 B cells were transferred i.v. into CD45.1−CD45.2+
wild-type mice, which were immunized i.p. with 100 µg of
NP-CGG/alum on day 0, followed by tamoxifen injection
p.o. on day 6, 7, and 8 to induce Foxo1 deletion and BATF
expression, and analysis on day 15.
Statistical analysis
Statistical analyses were performed with a two-tailed unpaired Student’s t test, a two-tailed paired Student’s t test, or a
Mann-Whitney test using GraphPad Prism software.
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